Frontiers in systems biology · 2026
Computational analysis and validation of UGT1A1/4 missense variants impacting tecovirimat metabolism in monkeypox patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdelazim Amro A, Hassanein Sameh E, Maged Mohamad, Al-Theyab Nada S, Kimiko Itoh, Attia Kotb A
Аннотация
INTRODUCTION: Single nucleotide polymorphisms (SNPs) in genes encoding drug-metabolizing enzymes can significantly impact a patient's response to medication. Uridine diphosphate glucuronosyltransferase 1 family A1 and A4 (UGT1A1/4) are crucial enzymes for metabolizing tecovirimat, the first oral antiviral drug approved for treating the monkeypox virus.
METHODS: This study used a comprehensive in-silico workflow to assess the deleterious effects of 842 missense mutations and 308 SNPs in the non-coding regions of the UGT1A1 gene, alongside 700 missense mutations and 324 SNPs in the non-coding regions of the UGT1A4 gene. An ensemble of in-silico prediction, structural modelling, and docking tools was employed.
RESULTS: We identified six missense variants that may compromise the structural integrity and function of the UGT1A1/4 enzymes. Specifically, the UGT1A1 SNPs G308R, P356T and G374S, while in UGT1A4 the SNPs G309R, P357T and G375S, were predicted to be the most harmful missense SNPs.
DISCUSSION: These mutations could affect drug-enzyme binding, potentially altering tecovirimat's therapeutic efficacy.
METHODS: This study used a comprehensive in-silico workflow to assess the deleterious effects of 842 missense mutations and 308 SNPs in the non-coding regions of the UGT1A1 gene, alongside 700 missense mutations and 324 SNPs in the non-coding regions of the UGT1A4 gene. An ensemble of in-silico prediction, structural modelling, and docking tools was employed.
RESULTS: We identified six missense variants that may compromise the structural integrity and function of the UGT1A1/4 enzymes. Specifically, the UGT1A1 SNPs G308R, P356T and G374S, while in UGT1A4 the SNPs G309R, P357T and G375S, were predicted to be the most harmful missense SNPs.
DISCUSSION: These mutations could affect drug-enzyme binding, potentially altering tecovirimat's therapeutic efficacy.